159 related articles for article (PubMed ID: 22413846)
1. Alterations of global histone H4K20 methylation during prostate carcinogenesis.
Behbahani TE; Kahl P; von der Gathen J; Heukamp LC; Baumann C; Gütgemann I; Walter B; Hofstädter F; Bastian PJ; von Ruecker A; Müller SC; Rogenhofer S; Ellinger J
BMC Urol; 2012 Mar; 12():5. PubMed ID: 22413846
[TBL] [Abstract][Full Text] [Related]
2. Global levels of histone modifications predict prostate cancer recurrence.
Ellinger J; Kahl P; von der Gathen J; Rogenhofer S; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Büttner R; Müller SC; Bastian PJ; von Ruecker A
Prostate; 2010 Jan; 70(1):61-9. PubMed ID: 19739128
[TBL] [Abstract][Full Text] [Related]
3. Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer.
Schneider AC; Heukamp LC; Rogenhofer S; Fechner G; Bastian PJ; von Ruecker A; Müller SC; Ellinger J
BJU Int; 2011 Oct; 108(8 Pt 2):E290-6. PubMed ID: 21627749
[TBL] [Abstract][Full Text] [Related]
4. The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters.
Ngollo M; Lebert A; Dagdemir A; Judes G; Karsli-Ceppioglu S; Daures M; Kemeny JL; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon D
BMC Cancer; 2014 Dec; 14():994. PubMed ID: 25535400
[TBL] [Abstract][Full Text] [Related]
5. Decoding the histone H4 lysine 20 methylation mark.
Balakrishnan L; Milavetz B
Crit Rev Biochem Mol Biol; 2010 Oct; 45(5):440-52. PubMed ID: 20735237
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.
Barros-Silva D; Costa-Pinheiro P; Duarte H; Sousa EJ; Evangelista AF; Graça I; Carneiro I; Martins AT; Oliveira J; Carvalho AL; Marques MM; Henrique R; Jerónimo C
Cell Death Dis; 2018 Feb; 9(2):167. PubMed ID: 29415999
[TBL] [Abstract][Full Text] [Related]
7. Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer.
Ellinger J; Kahl P; von der Gathen J; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Bastian PJ; von Ruecker A; Müller SC; Rogenhofer S
Cancer Invest; 2012 Feb; 30(2):92-7. PubMed ID: 22149091
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
9. Histone lysine methylation exhibits a distinct distribution during spermatogenesis in pigs.
An J; Qin J; Wan Y; Zhang Y; Hu Y; Zhang C; Zeng W
Theriogenology; 2015 Dec; 84(9):1455-62. PubMed ID: 26409824
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
11. Histone H4K20 tri-methylation at late-firing origins ensures timely heterochromatin replication.
Brustel J; Kirstein N; Izard F; Grimaud C; Prorok P; Cayrou C; Schotta G; Abdelsamie AF; Déjardin J; Méchali M; Baldacci G; Sardet C; Cadoret JC; Schepers A; Julien E
EMBO J; 2017 Sep; 36(18):2726-2741. PubMed ID: 28778956
[TBL] [Abstract][Full Text] [Related]
12. H4K20 methylation regulates quiescence and chromatin compaction.
Evertts AG; Manning AL; Wang X; Dyson NJ; Garcia BA; Coller HA
Mol Biol Cell; 2013 Oct; 24(19):3025-37. PubMed ID: 23924899
[TBL] [Abstract][Full Text] [Related]
13. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.
Paradowska A; Fenic I; Konrad L; Sturm K; Wagenlehner F; Weidner W; Steger K
Int J Oncol; 2009 Jul; 35(1):87-96. PubMed ID: 19513555
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
15. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
García-Tobilla P; Solórzano SR; Salido-Guadarrama I; González-Covarrubias V; Morales-Montor G; Díaz-Otañez CE; Rodríguez-Dorantes M
Gene; 2016 Nov; 593(2):292-301. PubMed ID: 27570179
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
20. P110β Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer.
Pang J; Yang YW; Huang Y; Yang J; Zhang H; Chen R; Dong L; Huang Y; Wang D; Liu J; Li B
Prostate; 2017 Feb; 77(3):299-308. PubMed ID: 27800642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
